[Table/Fig-6]:

Studies depicting effects of INF alpha in treatment of RAS.

STUDY	SUBJECTS	TREATMENT	EFFECTS
Hamuryudan V et al., (1990) [51]	Twenty patients with oral aphthous lesions associated with Behcet’s syndrome (twelve-week open trial).	Topical recombinant IFN-α 2c was applied on the aphthous lesions for four weeks.	Significant decline in the number of aphthae in the post-treatment phase.
Hutchinson VA et al., (1990) [52]	Double-blind, placebo-controlled study.	Recombinant human IFN-α 2a was administered orally once a day at a low concentration (1,200 IU/day).	All IFN-α 2a treated patients had complete remission of their aphthae within a 2-week period. The placebo control patients had no change in their condition.
Kiliç H et al., (2009) [53]	Eighty-four patients with RAS associated with BD.	Low-dose natural human IFN-α was administered by oral mucosal route.	No beneficial effects.
Alpsoy E et al., (2002) [54]	Randomized double-blind placebo-controlled study on 50 patients with BD.	IFN-α -2a, 6 x 10(6) IU was given subcutaneously 3 times per week or placebo for 3 months, and examined clinically at weekly intervals.	IFN-α -2a treatment significantly decreased the pain and duration of oral ulcers.
Karagiannidis I et al., (2015) [55]	37-year-old woman suffering from oral ulcers associated with Adamantiades-Behçet disease.	Longterm interferon-α-2a was given.	Reduction of the clinical manifestations but there was occasional occurrence of oral ulcers.
Kötter I et al., (2004) [56]	50 patients with BD	Recombinant human IFN-α 2a subcutaneous dose of 6 x 10(6) units subcutaneously daily followed by dose reduction.	Only 36% of oral aphthous ulcers responded.